Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon

#MindfulMondays with Miss SA

teen suicide icon


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue1

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

A study in PLoS Medicine suggests that the apparent clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses (second-generation anti-psychotic drugs) may be enhanced by the selective reporting of trials of these drugs in medical journals -- a phenomenon called publication bias. This finding is important as the results of published trials influence clinicians' decisions to prescribe drugs.

The authors, led by Erick Turner from Oregon Health & Science University in Portland, USA, say: "Selective reporting of research results undermines the integrity of the evidence base, which ultimately deprives clinicians of accurate data for prescribing decisions."

The authors reached these conclusions by reviewing 24 FDA-registered premarketing trials for eight second-generation antipsychotics -- aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection, and ziprasidone -- and then comparing these trials with the results conveyed in subsequent articles in medical journals.

The authors found that four premarketing trials submitted to the FDA remained unpublished and that all of the unpublished trials showed negative results -- three showed the new anti-psychotic had no statistically significant advantage over placebo, and in one trial the new drug was statistically inferior to a much less expensive competing drug.

In the published trials, there was some evidence that the journal articles over-emphasised efficacy of the new drug. For example, the FDA review revealed that one of the newer drugs, iloperidone, was statistically inferior to three different competing drugs, but this information was not mentioned in the corresponding journal articles.

On the other hand, when the authors used meta-analysis to combine trial data and compare all eight drugs to placebo, they found that publication bias had little effect on their overall apparent efficacy. Of more concern was that some negative data remain unreported, potentially misleading clinicians.

The authors conclude: "The magnitude of publication bias found for antipsychotics was less than that found previously for antidepressants, possibly because antipsychotics demonstrate superiority to placebo more consistently."

They continue: "With further studies investigating publication bias in other drug classes, a more accurate evidence base can emerge. To that end, increased access to FDA reviews has been advocated. At the present time, the FDA is not as transparent with its clinical trial data as it could be."

The authors add: "it is encouraging that the FDA has convened a Transparency Task Force. If the agency fulfills its mission to increase transparency, the public health will surely benefit."


Our Sponsors

Our Partners